Guideline for radioiodine therapy for benign thyroid diseases (version 4)

• Published in: Nuclear medicine Vol. 46; no. 5; p. 220
• Main Authors: Dietlein, M, Dressler, J, Grünwald, F, Leisner, B, Moser, E, Reiners, Chr, Schicha, H, Schneider, P, Schober, O
• Format: Journal Article
• Language: German
• Published: Germany 2007
• Subjects: Combined Modality Therapy; Graves Disease - radiotherapy; Humans; Iodine Radioisotopes - therapeutic use; Practice Guidelines as Topic; Recurrence; Thyroid Diseases - radiotherapy; Thyroid Diseases - surgery
• ISSN: 0029-5566
• DOI: 10.1160/nukmed-0287

Version 4 of the guideline for radioiodine therapy for benign thyroid diseases includes an interdisciplinary consensus on decision making for antithyroid drugs, surgical treatment and radioiodine therapy. The quantitative description of a specific goiter volume for radioiodine therapy or operation was cancelled. For patients with nodular goiter with or without autonomy, manifold circumstances are in favor of surgery (suspicion on malignancy, large cystic nodules, mediastinal goiter, severe compression of the trachea) or in favor of radioiodine therapy (treatment of autonomy, age of patient, co-morbidity, history of prior subtotal thyroidectomy, profession like teacher, speaker or singer). For patients with Graves' disease, radioiodine therapy or surgery are recommended in the constellation of high risk of relapse (first-line therapy), persistence of hyperthyroidism or relapse of hyperthyroidism. After counseling, the patient gives informed consent to the preferred therapy. The period after radioiodine therapy of benign disorders until conception of at least four months was adapted to the European recommendation.